22 oktober 2026
gret34t3
Stel uw vraag
Meer informatie nodig? Stel uw vraag aan één van onze medewerkers
gwe433
22 oktober 2026
Meer informatie nodig? Stel uw vraag aan één van onze medewerkers
gwe433
Drug repurposing means identifying new uses for medicines that already exist and have proven safe. This can make the road to treatment considerably shorter. “Gene therapies that can cure rare diseases will take many years to reach patients. Repurposing existing medicines can treat their symptoms and improve their quality of life much sooner,” the coordinators explain. SIMPATHIC, short for “Accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular disorders by exploiting SIMilarities in clinical and molecular PATHology”, received EU funding under Horizon Europe's health call for rare diseases to do exactly that. Neth-ER spoke with Prof. Dr. Peter-Bram 't Hoen of Radboudumc and Prof. Dr. Clara van Karnebeek of Amsterdam UMC.
Neth-ER publishes recommendations for dual-use R&I in Horizon Europe 2028–2034
Canada en de EU streven naar intensievere samenwerking op Erasmus+ en Horizon Europe
Neth-ER publishes its reaction to the ITRE reports on FP10 and the ECF
Horizon Europe investeert 411 miljoen euro in onderzoeksinfrastructuren